Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

The DDR1 receptor tyrosine kinase is activated by matrix collagens and has been implicated in numerous cellular functions such as proliferation, differentiation, adhesion, migration, and invasion. Here we report the discovery of a potent and selective DDR1 inhibitor, DDR1-IN-1, and present the 2.2 Å...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Kim, H, Tan, L, Weisberg, E, Liu, F, Canning, P, Choi, H, Ezell, SA, Wu, H, Zhao, Z, Wang, J, Mandinova, A, Griffin, J, Bullock, A, Liu, Q, Lee, S, Gray, N
Format:	Journal article
Sprache:	English
Veröffentlicht:	2013

Ähnliche Einträge

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor.
von: Kim, H, et al.
Veröffentlicht: (2014)

Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors
von: Canning, P, et al.
Veröffentlicht: (2014)

Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
von: Canning, P, et al.
Veröffentlicht: (2014)

Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum
von: Maria G. Nava, et al.
Veröffentlicht: (2023-02-01)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
von: López-Ramos, M, et al.
Veröffentlicht: (2010)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
von: López-Ramos, M, et al.
Veröffentlicht: (2010)

Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation
von: William A. Denny, et al.
Veröffentlicht: (2021-11-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
von: Panupong Mahalapbutr, et al.
Veröffentlicht: (2024-02-01)

Discovery of Novel Naphthoquinone–Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling
von: Ronnakorn Leechaisit, et al.
Veröffentlicht: (2023-08-01)

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
von: Patrice Dubreuil, et al.
Veröffentlicht: (2009-09-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
von: Xu H, et al.
Veröffentlicht: (2019-07-01)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
von: Sudarshan R Iyer, et al.
Veröffentlicht: (2023-10-01)

Recent Advances in Discovery of New Tyrosine Kinase Inhibitors Using Computational Methods
von: Vesna Rastija
Veröffentlicht: (2019-08-01)

Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics
von: Chunmin Yang, et al.
Veröffentlicht: (2022-05-01)

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.
von: Hellwig, S, et al.
Veröffentlicht: (2012)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights (September, pg 3175, 2010)
von: Lopez-Ramos, M, et al.
Veröffentlicht: (2011)

Kindlin-3 inactivation mediates melanoma agressiveness through crosstalk with the collagen-activated tyrosine kinase receptor DDR1
von: C. Reger de Moura, et al.
Veröffentlicht: (2024-01-01)

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
von: Ellen Weisberg, et al.
Veröffentlicht: (2013-01-01)

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
von: Ian M. Catlett, et al.
Veröffentlicht: (2023-01-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
von: Maria Dimou, et al.
Veröffentlicht: (2014-01-01)

TYROSINE KINASE INHIBITORS AND PREGNANCY
von: Elisabetta Abruzzese, et al.
Veröffentlicht: (2014-04-01)

Second-generation inhibitors of Bruton tyrosine kinase
von: Jingjing Wu, et al.
Veröffentlicht: (2016-09-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
von: Cornelius Hempel, et al.
Veröffentlicht: (2017-01-01)

Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents
von: Yangyang Yao, et al.
Veröffentlicht: (2017-10-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
von: John J. Ryan, MD
Veröffentlicht: (2016-12-01)

Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
von: Zhao, Z, et al.
Veröffentlicht: (2014)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
von: Ainun Nizar Masbuchin, et al.
Veröffentlicht: (2022-09-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
von: G. V. Lukina, et al.
Veröffentlicht: (2015-12-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
von: Huang JT, et al.
Veröffentlicht: (2022-11-01)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
von: Mark C Weir, et al.
Veröffentlicht: (2017-01-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
von: Tatsuki Shibuta, et al.
Veröffentlicht: (2022-06-01)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
von: Chris Liang, et al.
Veröffentlicht: (2022-03-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
von: Jiangnan Liu, et al.
Veröffentlicht: (2024-03-01)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
von: Wu J, et al.
Veröffentlicht: (2020-09-01)

Integrating machine learning and structure-based approaches for repurposing potent tyrosine protein kinase Src inhibitors to treat inflammatory disorders
von: Muhammad Waleed Iqbal, et al.
Veröffentlicht: (2025-01-01)

Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
von: Pitsiou G, et al.
Veröffentlicht: (2014-10-01)

509 Potent and selective inhibition Of AXL receptor tyrosine kinase for the treatment of cancer
von: Matthew Walters, et al.
Veröffentlicht: (2020-11-01)

Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma
von: Wei Dai, et al.
Veröffentlicht: (2021-05-01)

Tetrahydroisoquinoline-7-carboxamide derivatives as new selective discoidin domain receptor 1 (DDR1) inhibitors
von: Bullock, A, et al.
Veröffentlicht: (2017)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
von: Evan Pisick, et al.
Veröffentlicht: (2004-01-01)